<DOC>
	<DOCNO>NCT00193648</DOCNO>
	<brief_summary>The current management primary FSGS predicate assumption disease cause immune-mediated disturbance glomerular barrier function . Therefore , treatment protocol involve immunosuppressive drug give singly combination . However , efficacy type therapy disappoint long-term prognosis renal survival patient resistant FSGS poor . An alternative approach target fibrosis pathway may represent novel approach treatment resistant FSGS . In R21 , investigator test hypothesis two novel agent - tumor necrosis factor-alpha ( TNF-α ) antagonist peroxisome proliferator activator receptor-gamma ( PPARγ ) agonist - administer safely patient resistant FSGS . In R21 feasibility/pilot phase , pharmacokinetic study conduct assess impact proteinuria kinetics novel drug child adult . Specific Aim # 1 : To assess safety tolerability two novel drug - TNF-α antagonist PPARγ agonist - patient resistant FSGS . Specific Aim # 2 : To conduct pharmacokinetic ( PK ) assessment select agent enable selection medication regimens investigation randomize Phase II study .</brief_summary>
	<brief_title>Pilot Studies Novel Therapies Treat Resistant Focal Segmental Glomerulosclerosis ( FSGS )</brief_title>
	<detailed_description>Description study visit Screening Visit : Eligibility Studies 1 . History physical examination 2 . Urine protein creatinine excretion . Proteinuria ( Up/c ) express protein : creatinine ratio ( mg : mg ) single early morning specimen . 3 . Serum creatinine calculate GFR . The GFR calculate use Schwartz formula patient 18 year age Cockroft-Gault 18 year old . 4 . Serum Na+ , K+ , HCO3- , Cl- , glucose , BUN , albumin , cholesterol , AST , ALT , alkaline phosphatase , CBC , ANA , CH50 , pregnancy test 5 . HIV , Hepatitis B C serology , do previous 12 month 6 . TB skin test , do previous 12 month 7 . Existing renal biopsy tissue assess subject diagnosis FSGS confirm FSGS-CT core pathologist ( screen failure ) . Baseline Visit : Week 0 Visit 1 . Serum glucose , albumin , creatinine concentration 2 . TNF-alpha level 3 . Baseline anti-adalimumab antibody ( AAA ) level patient assign Humira® treatment 4 . A urine , plasma , serum DNA sample collect storage NIDDK FONT Biorepositories Fisher Bioservice Rutgers Cell &amp; DNA Repository patient consent procedure . A request make store residual renal tissue collect clinical indication FONT trial NIDDK Biorepository . 5 . PK assessment ( see ) Follow-up Assessment : Week 2 , 4 , 8 , 12 Visits 1 . Interval history , physical examination , assessment adverse event 2 . Urine protein excretion 3 . Serum creatinine calculate GFR , serum Na+ , K+ , HCO3 , Cl- , glucose , BUN , ALT , AST visit 4 . Serum albumin , cholesterol , ANA , CH50 8-week visit , CBC visit except 2-week visit 5 . Trough serum adalimumab level patient assign receive Humira® visit except 2-week visit 6 . Serum AAA level 12-week visit patient assign Humira® treatment 7 . Pregnancy test 12-week visit Final Assessment : Week 16 Visit 1 . Interval history , physical examination , assessment adverse event 2 . Urine protein excretion 3 . Serum creatinine calculate GFR 4 . Serum Na+ , K+ , HCO3 , Cl- , glucose , BUN , albumin , cholesterol , AST , ALT , alkaline phosphatase , CBC , ANA , CH50 , serum TNF-alpha level 5 . Serum AAA level patient assign Humira® treatment 6 . Serum , plasma , urine sample NIDDK Biosample Repository Fisher Bioservice 7 . Assessment patient satisfaction treatment use TSQM 8 . Steady state PK assessment ( see ) The follow Table summarizes laboratory assessment R21 study . Study Medications : Study medication ship single batch sufficient complete 4-month treatment period . A supply ship participate site individual patient enrol . Please complete Site Registration Form provide complete accurate shipping address receipt study medication week , Monday though Friday 9 AM - 5 PM . This information forward pharmaceutical company enable timely shipment drug site . Formulation administration experimental novel therapy Adalimumab ( Humira® ) : TNF-α antibody BB-IND # 11714 : This medication provide Abbott Laboratories available liquid . It administer subcutaneous injection every week . The therapeutic dose adalimumab 24 mg/m2 maximum 40 mg/dose every week entire treatment period . Patients instructed rotate site injection . In order reduce pain associate biweekly adalimumab injection , patient apply EMLA crème steroid inhaler spray prior administration medication . After injection complete , patient take Tylenol need apply ice site symptomatic pain relief . Patients receive Humira® require write date time drug administration bring administration log study visit . In addition , patient assign Humira® arm , per protocol dose schedule list week optimal date drug administration send medication site . This sheet use facilitate schedule visit share patient . Rosiglitazone ( Avandia® ) : PPARgamma agonist IND69,782 : This medication provide Glaxo Smith Kline available pill . It administer orally two divide daily dos . The therapeutic dose rosiglitazone 3 mg/m2/day administer two divided dos maximum 4 mg twice day . The twice daily dose schedule base study indicate great antiproteinuric effect rosiglitazone type 2 diabetes administer manner . Pharmacokinetic ( PK ) Studies Sampling Scheme : The blood urine collection scheme PK analysis conduct 48 hour GCRC patient schedule receive first dose ( single dose PK assessment ) adalimumab rosiglitazone 8th dose adalimumab ( ~steady state 105 day ) 4th month rosiglitazone therapy multiple dose PK assessment . A blood sample , 2.5-4 ml/sample ( 1-2.5 ml plasma/serum ) , drawn time point . For adalimumab , total 6 serum sample ( 4 ml , 24 ml blood total ) obtain . For rosiglitazone total 11 plasma sample ( 2.5 ml , 25 ml blood total ) obtain 48-hour PK study . The total amount blood drawn &lt; 3 ml/kg period . Urine collect follow interval : 0-2 , 2-12 , 12-24 , 24-36 , 36-48 hour . The total volume urine time interval record mL aliquot analyze protein : creatinine ratio local laboratory . The measurement urinary protein excretion 48 hour period use correlate PK parameter study medication concurrent level proteinuria . An aliquot urine sample collect time interval save specimen kit determination urinary excretion rosiglitazone . However , adalimumab measure urine , urinary excretion monoclonal antibody perform aliquot urine NOT save specimen kit measurement Humira® . If patient must go home first day test , return GCRC day 2 repeat blood draw return urine collection . The exact sampling time ( hour ) 48-hour PK study novel therapy , coincide midpoint urine collection ( see ) , outline follow Table : DRUG 0 0.5 1 2 4 6 8 12 18 30 42 Adalimumab X X X X X X Rosiglitazone* X X X X X X X X X X X - Serum glucose concentration measure time point . Trough serum adalimumab level draw 1 week first dose drug part PK study part formal patient visit . In addition PK study , trough serum adalimumab level also draw prior dose 2- , 4- , 8- , 12-week visit .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>1 . Aged 242 year onset proteinuria 2 . Aged ≤ 42 year time randomization ( randomization date 43rd birthday ) 3 . Estimated glomerular filtration rate ( GFR ) ≥ 40 ml/min/1.73 m2 recent measurement prior randomization 1 . For patient &lt; age 18 year : Schwartz formula 2 . For patient ≥ age 18 year : CockroftGault formula 4 . Up/c &gt; 1.0 g/g creatinine first morning void time randomization 5 . Biopsy confirm primary FSGS ( include subtypes ) study pathologist . 6 . Steroid resistance : During last treatment course high dose steroid prior randomization , patient must demonstrate steroid resistance define complete remission proteinuria ( Up/c &lt; 0.2 dipstick urine protein negative/trace ) subsequently . The course steroid treatment defines resistance must equivalent least 4 week every day dose minimum cumulative dose 56 mg/kg 1680 mg prednisone equivalent . 7 . May take angiotensinconverting enzyme inhibitor ( ACEI ) , angiotensin receptor block agent ( ARB ) , vitamin E , lipid lower therapy 8 . Willingness comply clinical trial protocol , medication , followup visit , etc . 9 . Screen failure FSGSCT base prior treatment exclude medication 10 . Treatment failure FSGSCT base failure achieve remission 26 week 52 week test therapy , i.e. , cyclosporine mycophenolate mofetil ( MMF ) + oral dexamethasone pulse Exclusion Criteria 1 . Secondary FSGS 2 . Treated cyclophosphamide , chlorambucil , levamisole , methotrexate , nitrogen mustard , immunosuppressive medication 30 day prior randomization 3 . Lactation , pregnancy , refusal birth control woman child bear potential 4 . Participation another therapeutic trial concurrently 30 day prior randomization 5 . Active/serious infection ( include , limited hepatitis B C , HIV ) 6 . Malignancy 7 . Systemic lupus erythematosus ( SLE ) multiple sclerosis 8 . Hepatic disease define serum AST/ALT &gt; 2.5X upper limit normal 9 . Patients blood pressure &gt; 140/95 &gt; 95th percentile age/height receive maximal dos 3 antihypertensive agent . 10 . Diabetes mellitus ( DM ) type I II . 11 . Hematocrit &lt; 30 % 12 . Organ transplantation 13 . Obesity ( base estimate dry weight disease onset prior steroid therapy ) define : 1 . Body mass index ( BMI ) &gt; 97th percentile age age 220 year 2 . BMI &gt; 40 kg/m2 age ≥ 21 year 14 . Allergy study medication 15 . Inability consent/assent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>FSGS</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>PPAR-gamma agonist</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>TNF-alpha antagonist</keyword>
	<keyword>Steroid immunosuppressive drug resistance</keyword>
	<keyword>Resistant primary FSGS</keyword>
</DOC>